Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
Cidara Therapeutics (Nasdaq: CDTX) has announced concurrent underwritten public offerings of its common stock and Series X Convertible Preferred Stock. The offerings are independent and subject to customary closing conditions, with Cantor Fitzgerald & Co. as the sole book-running manager. The company has granted a 30-day option to the underwriter to purchase an additional 15% of the common shares. The offerings are made under a shelf registration statement effective with the SEC. Cidara is focused on long-acting therapeutics, particularly its lead Phase 3 antifungal candidate, rezafungin, and other innovations targeting serious diseases.
- Concurrent underwritten public offerings of common stock and Series X Convertible Preferred Stock to raise capital.
- Lead candidate rezafungin is in Phase 3 trials, indicating advancement in product pipeline.
- Public offerings may cause dilution of existing shares.
- Market conditions and customary closing may affect the completion of offerings.
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock. The closing of each proposed offering is not contingent upon the closing of the other. All shares to be sold in the offerings will be sold by Cidara, subject to customary closing conditions.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for each offering.
The Company also has granted to the underwriter a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock offered in the public offering.
The securities described above are being offered by Cidara pursuant to a shelf registration statement, which has been declared effective by the Securities and Exchange Commission (SEC). Preliminary prospectus supplements and the accompanying prospectus relating to the offerings will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplements and accompanying prospectus relating to these offerings, when available, may be obtained from: Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California.
Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Cidara’s expectations regarding the timing and completion of its public offerings and Cidara’s expectations with respect to granting the underwriter a 30-day option to purchase additional shares. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offerings, as well as risks and uncertainties associated with Cidara’s business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the prospectus supplements related to the public offerings that will be filed with the SEC and in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently filed with the SEC. There can be no assurances that Cidara will be able to complete either or both of the proposed offerings on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Cidara undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
What are the details of Cidara's public offerings on March 2, 2023?
Who is managing Cidara's stock offerings?
What is the purpose of Cidara's public offerings?
How might Cidara's offerings affect existing shareholders?